Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial Posted on February 20, 2025April 3, 2025 by recce_com Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial
Recce soars on phase II skin infection trial results Posted on February 17, 2025 by recce_com Recce soars on phase II skin infection trial results
Recce Pharmaceuticals doses all patients in phase II skin infection trial Posted on January 29, 2025 by recce_com Recce Pharmaceuticals doses all patients in phase II skin infection trial
Recce Pharmaceuticals doses all patients in Phase 2 clinical trial of RECCE® 327 topical gel for skin infections Posted on January 21, 2025 by recce_com Recce Pharmaceuticals doses all patients in Phase 2 clinical trial of RECCE® 327 topical gel for skin infections
Recce gets Indonesian nod for phase III trial of diabetic foot infection treatment Posted on December 9, 2024 by recce_com Recce gets Indonesian nod for phase III trial of diabetic foot infection treatment
Complete patent protection for 2 Recce anti-infective treatments Posted on November 26, 2024 by recce_com Complete patent protection for 2 Recce anti-infective treatments
Recce green lit to begin dosing in registrational Phase 3 trial for diabetic foot infections Posted on November 11, 2024 by recce_com Recce green lit to begin dosing in registrational Phase 3 trial for diabetic foot infections
From No More Tears to no more superbug fears Posted on October 21, 2024 by recce_com From No More Tears to no more superbug fears
Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead! Posted on October 16, 2024 by recce_com Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!
